Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients
Author:
Affiliation:
1. Department of Clinical and Experimental Medicine; Foggia University; Foggia Italy
2. Division of Oral Medicine and Dentistry; Brigham and Women's Hospital; Boston MA USA
Publisher
Wiley
Subject
General Dentistry,Otorhinolaryngology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/odi.12795/fullpdf
Reference154 articles.
1. Everolimus for patients with metastatic renal cell carcinoma refractory to anti-VEGF therapy: Results of a pooled analysis of non-interventional studies;Albiges;European Journal of Cancer,2015
2. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer;Amato;Cancer,2009
3. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab;Andre;Journal of Clinical Oncology,2010
4. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial;Andre;The Lancet. Oncology,2014
5. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer;Armstrong;Clinical Genitourinary Cancer,2013
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. MASCC/ISOO Clinical Practice Statement: Management of oral complications of targeted therapy;Supportive Care in Cancer;2024-07-25
2. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan;Cancer Treatment Reviews;2024-04
3. Oral adverse drug reactions;Handbook of Dental Therapeutics;2024-03-31
4. Disproportionality Analysis of Stomatitis Associated with Anticancer Drugs Using the Japanese Adverse Drug Event Report Database;Oncology;2024
5. Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy;International Journal of Molecular Sciences;2023-05-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3